Ultralife Corporation Reports Third Quarter Results

Rhea-AI Summary

Ultralife (NASDAQ: ULBI) reported Q3 2025 results: revenue $43.4M (+21.5% YoY; $36.6M ex-Electrochem, +2.5%), gross profit $9.6M (22.2% margin vs 24.3% a year ago), and GAAP EPS ($0.07) vs $0.02 prior year. The company recorded a $1.1M one-time charge (including $0.5M to close Calgary) leading to an operating loss of $1.0M; adjusted EBITDA $2.0M. Backlog exited Q3 at $90.1M vs $84.5M in Q2. Management expects Calgary closure complete in Q1 2026 with ~<$0.8M estimated annual savings.

Positive

• Revenue +21.5% YoY to $43.4M
• Excluding Electrochem, sales +2.5% YoY
• Backlog grew to $90.1M exiting Q3
• Adjusted EBITDA of $2.0M in Q3

Negative

• Gross margin down to 22.2% from 24.3%
• Operating loss $1.0M includes $1.1M one-time charges
• Operating expenses rose to 24.4% of revenue
• Interest expense from Electrochem acquisition financing

Insights

Corporate Finance Analyst

Revenue rose largely from the Electrochem acquisition; underlying organic growth was modest and GAAP results were hurt by one-time charges.

Revenue increased to $43.4 million, up 21.5% year-over-year, with organic sales growth of 2.5% excluding Electrochem; adjusted EBITDA edged to $2.0 million or 4.7% of sales, and trailing twelve‑month adjusted EBITDA was $15.5 million or 8.3% of sales. Gross margin compressed to 22.2% from 24.3%, driven by manufacturing inefficiencies and mix in the Battery & Energy Products segment, while Communications Systems margins improved to 23.3%.

One-time items drove the GAAP loss: an operating loss of $1.0 million and net loss attributable of $1.2 million or ($0.07) per share, reflecting $1.1 million of non-recurring costs including a $0.5 million Calgary facility closure charge. Management cites expected annual run-rate savings of about $0.8 million after the closure completes in Q1 2026. Watch backlog trends (exiting backlog $90.1 million) and quarterly margin recovery over the next four quarters as evidence of operational improvements and integration benefits.

NEWARK, N.Y., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2025 with the following results:

• Sales of $43.4 million increased 21.5% from $35.7 million for the third quarter of 2024; excluding Electrochem, sales of $36.6 million increased 2.5%
• Gross profit of $9.6 million, or 22.2% of revenue, compared to $8.7 million, or 24.3% of revenue, for the third quarter of 2024
• Operating loss of $1.0 million, reflecting one-time non-recurring costs of $1.1 million, including a $.5 million provision to close our Calgary facility, compared to operating income of $0.5 million for the third quarter of 2024
• GAAP EPS of ($0.07) compared to $0.02 for the third quarter of 2024
• Adjusted EBITDA of $2.0 million compared to $1.9 million for the third quarter of 2024
• Backlog of $90.1 million exiting the third quarter of 2025 compared to $84.5 million exiting the second quarter of 2025

During the third quarter of 2025, Ultralife made the decision to close its battery pack assembly facility located in Calgary, Canada. Accordingly the Company recorded a $.5 million charge to cover employee severance and termination costs, the remaining lease costs which run through July 31, 2026 and the estimated costs to close the facility and relocate the equipment and inventory to the Company’s facility in Houston, Texas. Management expects to complete the closure in the first quarter of 2026 and to realize estimated annual savings of approximately $.8 million thereafter primarily resulting from the reduction of labor and the elimination of the leased facility.

“Although revenue grew 2.5% organically and 21.5% including the Electrochem acquisition for the third quarter, supply chain issues caused manufacturing inefficiencies in our Battery & Energy Products business and orders continued to be delayed in our Communications Systems business, both of which impacted overall profitability. In response, we are intensifying our lean and process improvement initiatives, improving supply chain resiliency and rationalizing our manufacturing operations,” said Mike Manna, President and Chief Executive Officer.

“These actions are critical to ensuring we are best prepared to optimize the operating leverage of our business model as we advance several new products into qualification and production, and capitalize on an expanding pipeline of opportunities consisting primarily of large, multi-year programs,” added Manna. “Our priorities remain converting long-term new product development efforts into revenue, advancing vertical integration in the oil & gas segment, and maintaining a strong focus on operational efficiency initiatives to deliver sustainable profitable growth and maximizing the value of our global brand.”

Third Quarter 2025 Financial Results

Revenue was $43.4 million, an increase of $7.7 million, or 21.5%, as compared to revenue of $35.7 million for the third quarter of 2024. Battery & Energy Products sales increased 22.8% to $39.9 million compared to $32.5 million last year reflecting the inclusion of Electrochem Solutions, Inc. (“Electrochem”). Excluding Electrochem, Battery & Energy Products sales increased 1.9% with government/defense sales increasing 19.0%, reflecting strong demand from a U.S.-based global prime, partially offset by a 5.7% decrease in commercial sales, primarily reflecting declines in oil & gas and medical sales. Communications Systems sales increased 8.2% to $3.4 million compared to $3.2 million for the same period last year.

Gross profit was $9.6 million, or 22.2% of revenue, compared to $8.7 million, or 24.3% of revenue, for the same quarter a year ago. Battery & Energy Products gross margin was 22.1%, compared to 24.7% last year, primarily due to manufacturing inefficiencies resulting from quality issues associated with some incoming raw materials lowering factory throughput at some of our locations and less favorable sales mix. Communications Systems gross margin was 23.3% compared to 20.0% last year, primarily due to product mix.

Operating expenses were $10.6 million, compared to $8.2 million for the third quarter of 2024, reflecting the inclusion of Electrochem and one-time non-recurring costs of $1.1 million related to the closing of our Calgary facility, costs related to our acquisition of Electrochem and transition to Ultralife systems, and litigation expenses incurred for our cyber insurance claim. Operating expenses were 24.4% of revenue compared to 22.9% of revenue for the year-earlier period. Excluding the one-time costs, operating expenses were 21.9% of revenues for the third quarter of 2025.

Operating loss was $1.0 million compared to operating income of $.5 million last year, primarily resulting from the one-time non-recurring expenses incurred and lower gross margin for our Battery & Energy Products segment in 2025.  

Other expense, reported below operating income was $.8 million, comprised of interest expense from the financing of our Electrochem acquisition on October 31, 2024 and foreign currency gains from the strengthening of the U.S. dollar, compared to $.2 million for the same period last year.   

Net (loss) income attributable to Ultralife Corporation was ($1.2) million or ($0.07) per basic and diluted share on a GAAP basis, compared to $.3 million or $0.02 per diluted share for the third quarter of 2024.

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense, was $2.0 million for the third quarter of 2025, or 4.7% of sales, compared to $1.9 million, or 5.4% of sales, for the year-earlier period. On a trailing twelve-month basis, adjusted EBITDA was $15.5 million or 8.3% of sales.

See the “Non-GAAP Financial Measures” section of this release for a reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

Conference Call Information

Ultralife will hold its third quarter earnings conference call today at 8:30 ET.

To ensure a fast and reliable connection to our investor conference call, we now require participants dialing in by phone to register using the following link prior to the call: https://register-conf.media-server.com/register/BI0301fd92021249ef830e0c9c7be9f917. This will eliminate the need to speak with an operator. Once registered, dial-in information will be provided along with a personal identification number. Should you register early and misplace your details, you can simply click back on this same link at any time to register and view this information again. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include uncertain global economic conditions including the impact of tariffs and inflation, reductions in revenues from key customers, delays or reductions in U.S. and foreign military spending, acceptance of our new products on a global basis, and disruptions, delays or material price increases in our supply of raw materials and components due to business conditions, new or additional tariffs, global conflicts, weather or other factors not under our control. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (Dollars in Thousands)
(Unaudited)
ASSETS
		September 30, 2025					December 31, 2024
Current Assets:
Cash		$9,260					$6,854
Trade Accounts Receivable, Net		30,929					29,370
Inventories, Net		52,747					51,363
Prepaid Expenses and Other Current Assets		7,683					9,573
Total Current Assets		100,619					97,160
Property, Plant and Equipment, Net		40,536					40,485
Goodwill		45,336					45,006
Other Intangible Assets, Net		23,407					24,557
Deferred Income Taxes, Net		8,212					8,413
Other Non-Current Assets		4,136					4,830
Total Assets		$222,246					$220,451
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts Payable		$14,164					$14,160
Current Portion of Long-Term Debt		3,781					2,750
Accrued Compensation and Related Benefits		2,935					2,911
Accrued Expenses and Other Current Liabilities		12,818					9,470
Total Current Liabilities		33,698					29,291
Long-Term Debt, Net		46,518					51,502
Deferred Income Taxes		1,358					1,443
Other Non-Current Liabilities		3,239					4,028
Total Liabilities		84,813					86,264
Shareholders' Equity:
Common Stock		2,109					2,107
Capital in Excess of Par Value		192,622					191,828
Accumulated Deficit		(32,918)					(34,442)
Accumulated Other Comprehensive Loss		(3,058)					(4,006)
Treasury Stock		(21,492)					(21,492)
Total Ultralife Equity		137,263					133,995
Non-Controlling Interest		170					192
Total Shareholders’ Equity		137,433					134,187
Total Liabilities and Shareholders' Equity		$222,246					$220,451

ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In Thousands Except Per Share Amounts)
(Unaudited)
	Three-Month Period Ended				Nine-Month Period Ended
	September 30,		September 30,		September 30,		September 30,
	2025		2024		2025		2024
Revenues:
Battery & Energy Products	$39,946		$32,529		$132,134		$104,201
Communications Systems	3,425		3,165		10,544		16,403
Total Revenues	43,371		35,694		142,678		120,604
Cost of Products Sold:
Battery & Energy Products	31,126		24,482		101,039		77,215
Communications Systems	2,626		2,530		7,674		11,674
Total Cost of Products Sold	33,752		27,012		108,713		88,889
Gross Profit	9,619		8,682		33,965		31,715
Operating Expenses:
Research and Development	2,855		2,101		7,577		5,854
Selling, General and Administrative	7,715		6,070		21,684		17,370
Total Operating Expenses	10,570		8,171		29,261		23,224
Operating (Loss) Income	(951)		511		4,704		8,491
Other Expense	800		158		2,896		685
(Loss) Income Before Income Taxes	(1,751)		353		1,808		7,806
Income Tax (Benefit) Provision	(504)		74		306		1,630
Net (Loss) Income	(1,247)		279		1,502		6,176
Net (Loss) Income Attributable to Non-Controlling Interest	(27)		21		(22)		58
Net (Loss) Income Attributable to Ultralife Corporation	($1,220)		$258		$1,524		$6,118
Net (Loss) Income Per Share Attributable to Ultralife Common Shareholders – Basic	($.07)		$.02		$.09		$.37
Net (Loss) Income Per Share Attributable to Ultralife Common Shareholders – Diluted	($.07)		$.02		$.09		$.37
Weighted Average Shares Outstanding – Basic	16,646		16,625		16,638		16,530
Weighted Average Shares Outstanding – Diluted	16,646		16,874		16,699		16,742

Non-GAAP Financial Measures

Adjusted EBITDA

In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to GAAP financial measures. We define adjusted EBITDA as net income attributable to Ultralife Corporation before net interest expense, provision for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile adjusted EBITDA to net income attributable to Ultralife Corporation, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

ULTRALIFE CORPORATION AND SUBSIDIARIES CALCULATION OF ADJUSTED EBITDA (Dollars in Thousands) (Unaudited)
	Three-Month Period Ended				Nine-Month Period Ended
	September 30, 2025		September 30, 2024		September 30, 2025		September 30, 2024
Net (Loss) Income Attributable to Ultralife Corporation	($1,220)		$258		$1,524		$6,118
Adjustments:
Interest Expense, Net	992		173		3,016		1,111
Income Tax (Benefit) Provision	(504)		74		306		1,630
Depreciation Expense	1,008		765		2,966		2,294
Amortization Expense	411		229		1,226		684
Stock-Based Compensation Expense	236		170		698		490
Severance and Other Costs for Plant Closure	491		-		641		-
Acquisition and Other Non-Recurring Costs	594		250		1,112		-
Non-Cash Purchase Accounting Adjustment	40		-		120		250
Adjusted EBITDA	$2,048		$1,919		$11,609		$12,577

Company Contact: Ultralife Corporation Philip A. Fain (315) 210-6110 pfain@ulbi.com

Investor Relations Contact: Alliance Advisors IR Jody Burfening/Alex Villalta (212) 838-3777 avillalta@allianceadvisors.com

FAQ

What were Ultralife (ULBI) Q3 2025 revenues and growth?

Ultralife reported $43.4M in Q3 2025 revenue, a 21.5% increase year-over-year.

How did the Electrochem acquisition affect Ultralife's Q3 2025 results?

Including Electrochem boosted sales; $36.6M ex-Electrochem implies +2.5% organic growth.

Why did Ultralife report an operating loss in Q3 2025?

An operating loss of $1.0M reflected $1.1M of one-time costs, including a $0.5M Calgary closure charge.

What is Ultralife's backlog at the end of Q3 2025?

Backlog exiting Q3 2025 was $90.1M, up from $84.5M exiting Q2 2025.

When will Ultralife complete the Calgary facility closure and expected savings?

Management expects closure complete in Q1 2026 with estimated annual savings of approximately $0.8M.

What were Ultralife's Q3 2025 adjusted EBITDA and GAAP EPS?

Adjusted EBITDA was $2.0M and GAAP EPS was ($0.07) for Q3 2025.